Melinta Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to introducing new antibiotics that meet the ever-present challenge posed by dangerous and increasingly resistant bacteria. We are completing Phase 3 development of our late-stage investigational antibiotic, Baxdela (delafloxacin), for serious hospital-treated skin infections known as acute bacterial skin and skin structure infections (ABSSSI). Melinta is also developing, through the application of Nobel Prize-winning science and a proprietary drug discovery platform, novel classes of antibiotics to treat the multi- and extremely-drug-resistant pathogens for which there are few to no options, known collectively as ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacter species and Escherichia coli), which cause the majority of life-threatening hospital infections. Melinta Therapeutics is privately held with offices in New Haven, CT and Lincolnshire, IL.